Abstract
26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0·5 mg/kg daily for 2 weeks and then 3 times a week at 0·5 mg/kg for 10 weeks. 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 551-555 |
| Number of pages | 5 |
| Journal | Lancet |
| Volume | 321 |
| Issue number | 8324 |
| DOIs | |
| Publication status | Published - Mar 12 1983 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES. / Aiuti, F.; Fiorilli, M.; Quinti, I.; Seminara, R.; Businco, L.; Galli, E.; Rossi, P.; Goldstein, G.
In: Lancet, Vol. 321, No. 8324, 12.03.1983, p. 551-555.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES
AU - Aiuti, F.
AU - Fiorilli, M.
AU - Quinti, I.
AU - Seminara, R.
AU - Businco, L.
AU - Galli, E.
AU - Rossi, P.
AU - Goldstein, G.
PY - 1983/3/12
Y1 - 1983/3/12
N2 - 26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0·5 mg/kg daily for 2 weeks and then 3 times a week at 0·5 mg/kg for 10 weeks. 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.
AB - 26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0·5 mg/kg daily for 2 weeks and then 3 times a week at 0·5 mg/kg for 10 weeks. 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.
UR - http://www.scopus.com/inward/record.url?scp=0020699783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020699783&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(83)92810-6
DO - 10.1016/S0140-6736(83)92810-6
M3 - Article
C2 - 6131256
AN - SCOPUS:0020699783
VL - 321
SP - 551
EP - 555
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 8324
ER -